235 related articles for article (PubMed ID: 17937591)
1. Management of lipids in the prevention of cardiovascular events.
Glassberg H; Rader DJ
Annu Rev Med; 2008; 59():79-94. PubMed ID: 17937591
[TBL] [Abstract][Full Text] [Related]
2. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
3. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
Nicholls SJ; Lundman P; Tardif JC
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Brown BG; Zhao XQ
Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
Raal FJ
Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
[TBL] [Abstract][Full Text] [Related]
7. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines.
Robinson JG; Ray K
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):586-90. PubMed ID: 26988588
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
9. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
10. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
[TBL] [Abstract][Full Text] [Related]
12. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
Windler E; Schöffauer M; Zyriax BC
Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
[TBL] [Abstract][Full Text] [Related]
14. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
15. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
16. Monotherapy vs combination therapy for dyslipidemia in the elderly.
Shepherd J
Am J Geriatr Cardiol; 2008; 17(2):108-13. PubMed ID: 18326949
[TBL] [Abstract][Full Text] [Related]
17. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
Lim S; Park YM; Sakuma I; Koh KK
Int J Cardiol; 2013 Jun; 166(1):8-14. PubMed ID: 22503572
[TBL] [Abstract][Full Text] [Related]
18. Total lipid management and cardiovascular disease in the dyslipidemia international study.
Ferrières J; Amber V; Crisan O; Chazelle F; Jünger C; Wood D
Cardiology; 2013; 125(3):154-63. PubMed ID: 23736147
[TBL] [Abstract][Full Text] [Related]
19. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
Packard CJ
Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807
[TBL] [Abstract][Full Text] [Related]
20. Effective low-density lipoprotein-lowering therapy: Implementation in clinical practice.
Sinning D; Landmesser U
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):71-76. PubMed ID: 28618905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
